(ANRO) Alto Neuroscience - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock •
ANRO: Depression, Schizophrenia, PTSD, Antidepressants, Cognitive Impairment
Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders. Its pipeline includes ALTO-100, currently in Phase 2b trials for major depressive disorder (MDD) and Phase 2a for post-traumatic stress disorder (PTSD). ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist, is in Phase 2b trials for MDD. The company also develops ALTO-101, a novel phosphodiesterase 4 inhibitor in Phase 1 for cognitive impairment in schizophrenia, and ALTO-203, a histamine H3 receptor inverse agonist in Phase 1 for MDD with high anhedonia. Additionally, ALTO-202, an NMDA receptor GluN2B subunit antagonist, is in Phase 1 for MDD. Alto Neuroscience also focuses on pharmacodynamically synergistic combinations and a biomarker platform to identify patient-specific treatment responses. Founded in 2019, the company is based in Los Altos, California.
From a technical standpoint, ANROs stock shows a declining trend, with SMA20 at 3.25, SMA50 at 3.90, and SMA200 at 8.47, indicating long-term downward momentum. Average volume of 410,875 shares suggests moderate liquidity, with an ATR of 0.31 reflecting limited price volatility. The stock last traded at 3.38.
Fundamentally, Alto Neuroscience has a market cap of $86.03M, with a P/B ratio of 0.51, indicating undervaluation relative to book value. The company reports a return on equity (RoE) of -34.81%, reflecting ongoing losses typical of early-stage biotech firms. With no P/E or P/S ratios due to lack of earnings or sales, the stock is speculative, driven by clinical trial outcomes and pipeline progression.
Over the next 3 months, ANRO is expected to remain under pressure, with SMA20 and SMA50 trending downward. Support may emerge near $3.00, while resistance could form at $4.00. ATR suggests limited volatility, with price movements likely confined to a narrow range. Fundamental catalysts, such as clinical trial updates, could drive short-term price movements.
Additional Sources for ANRO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ANRO Stock Overview
Market Cap in USD | 96m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2024-02-02 |
ANRO Stock Ratings
Growth 5y | -49.9% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -77.7 |
Analysts | 4.71/5 |
Fair Price Momentum | 2.06 USD |
Fair Price DCF | - |
ANRO Dividends
No Dividends PaidANRO Growth Ratios
Growth Correlation 3m | -56.7% |
Growth Correlation 12m | -83.5% |
Growth Correlation 5y | -85.6% |
CAGR 5y | -76.76% |
CAGR/Max DD 5y | -0.88 |
Sharpe Ratio 12m | 0.44 |
Alpha | -89.87 |
Beta | 1.96 |
Volatility | 90.49% |
Current Volume | 242.6k |
Average Volume 20d | 238.8k |
As of March 14, 2025, the stock is trading at USD 3.16 with a total of 242,600 shares traded.
Over the past week, the price has changed by -20.00%, over one month by -3.07%, over three months by -17.49% and over the past year by -77.75%.
Probably not. Based on ValueRay Analyses, Alto Neuroscience (NYSE:ANRO) is currently (March 2025) not a good stock to buy. It has a ValueRay Growth Rating of -49.87 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ANRO as of March 2025 is 2.06. This means that ANRO is currently overvalued and has a potential downside of -34.81%.
Alto Neuroscience has received a consensus analysts rating of 4.71. Therefor, it is recommend to buy ANRO.
- Strong Buy: 6
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ANRO Alto Neuroscience will be worth about 2.4 in March 2026. The stock is currently trading at 3.16. This means that the stock has a potential downside of -24.37%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 12.7 | 302.5% |
Analysts Target Price | 12.7 | 302.5% |
ValueRay Target Price | 2.4 | -24.4% |